Long-Term Viral Suppression in Masivukeni: A Multimedia ART Initiation and Adherence Intervention for Resource-Limited Settings


HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University; University of Cape Town
There are a growing number of people initiating ART in South Africa and globally, but long-term ART adherence and retention problems are an ongoing concern.

In resource-constrained settings, there is increasing reliance on lay counselors to provide ART adherence counseling.

There is a desire for standardized and effective ART adherence interventions that can be scaled-up and efficiently delivered by lay counselors.
Successful ART initiation and long-term adherence with sustained, suppressed viral load (VL) are essential to personal health & ending the global HIV epidemic.

Many adherence interventions are either modestly successful in the short-term (i.e., up to one-year follow-up) or have not shown intervention effect at one-year due to “ceiling effect”

Few have demonstrated long-term viral suppression, nor have studied (followed) patients beyond one year.
Masivukeni is a theoretically-derived, laptop-based multimedia behavioral intervention developed in collaboration with nurses, counselors, physicians, and patients in South Africa (SA).

Masivukeni is consistent with standard of care counseling (SOC) in SA (3-4 sessions, defaulter follow-up, support partner inclusion).

Masivukeni helps counselors deliver standardized messages; it tracks what content they have covered with each patient; and it conveys complex medical information in easy to understand ways, with videos, interactive activities, and visual images.
The Multimedia Intervention

"Being at the clinic takes too much time, and is too unpleasant"

"The medication makes me feel sick"

"When I drink too much, I forget to take my medications"
Sessions

Select a session so Practice Participant can get started!

- ⭐ Session 1: Getting Started
- ⭐ Session 2: Learning About HIV Treatment
- ⭐ Session 3: Good Adherence and Healthy Living
- ⭐ ARV Adherence Follow-up 1
- ⭐ ARV Adherence Follow-up 2
Choosing a Buddy
HIV Symptoms

BEFORE GOING ON ARVS
Key elements: video models

- Patients watched models of good/vs bad adherence practice and of problem solving.
Randomized controlled trial: Participants were randomized to Masivukeni or Standard of Care, at a 2:1 ratio, and followed for 12 months

- 3-4 sessions delivered prior to/during ART initiation
- Follow-up sessions for defaulters
- Treatment support with “buddies”
<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Masivukeni study participants at Baseline (N=432)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>N/Mean</th>
<th>%/SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>317</td>
<td>74%</td>
</tr>
<tr>
<td>Age (mean, SD)</td>
<td>33</td>
<td>8</td>
</tr>
<tr>
<td>Graduated from high school</td>
<td>127</td>
<td>30%</td>
</tr>
<tr>
<td>Currently working</td>
<td>184</td>
<td>43%</td>
</tr>
<tr>
<td>Income ≤R1500 per month</td>
<td>189</td>
<td>44%</td>
</tr>
<tr>
<td>Currently infected with TB</td>
<td>93</td>
<td>22%</td>
</tr>
<tr>
<td>CD4 count</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;200</td>
<td>171</td>
<td>40%</td>
</tr>
<tr>
<td>200-349</td>
<td>186</td>
<td>43%</td>
</tr>
<tr>
<td>≥350</td>
<td>75</td>
<td>17%</td>
</tr>
</tbody>
</table>
The *Masivukeni* intervention was highly acceptable to counselors and patients in busy SA clinics.

62% of the sample had viral loads in medical charts at 12 months, with very high viral suppression rates (95%), and no difference between study arms in viral load suppression nor in care retention, however:

- There was a strong trend in the Masivukeni arm for improved viral suppression when there was >50% participation by “buddy”; and

- A strong trend for women in the Masivukeni intervention to be more likely to initiate ART than women in the SOC; this effect was not found for men.
What about long-term viral suppression?

- Routine clinic viral loads (after ART initiation)
  - Approximately 4-months post ART-initiation
  - Approximately 12-months post ART-initiation
  - Then annually, unless otherwise indicated

- Data Sources
  - Clinic medical records
  - National Reference Laboratory
  - Centralized Electronic Medical Records
We collected all available VL data from all available sources, post 12-months.

- 345 participants had at least 2 VL data points
  - Mean first VL = 6 months (SD=4.7 months)
  - Mean last VL = 30 months (SD=9.7 months)

We then stratified the groups based on initial suppression rates, and

- We examined VL ‘change’: first to last VL
We used exact logistic regression to examine the effect of Masivukeni on VL change among those whose first VL was suppressed (<400 copies/mL) and those whose first VL was unsuppressed (>400 copies/mL), controlling for time between VLs.
Findings

Among people who were suppressed at first VL (n=314): 96% remained suppressed at last VL (no difference by treatment arm)

Among participants who were not suppressed at first VL (n=31):

Participants in Masivukeni were 12 times as likely to be suppressed at last VL compared to SOC

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Intervention</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Suppressed at last VL</td>
<td>21</td>
<td>68%</td>
<td>19</td>
</tr>
<tr>
<td>Not suppressed at last VL</td>
<td>10</td>
<td>32%</td>
<td>5</td>
</tr>
</tbody>
</table>

*p = .003*
Conclusions & Implications

- The majority of patients – who were retained in care, and had VL testing performed – did well in the 1st year after ART initiation, regardless of treatment arm

  - SOC, in the setting seems to be going relatively well; most patients (who remain in care) do not need extra attention

  - However, a substantial number of patients are not retained in care – they may or may not be virally suppressed; this remains a challenge in the setting

- There is a need for innovative interventions for care retention (most likely means addressing structural barriers / policy & social determinants of health)
A subset of patients who struggled to suppress viral load initially, benefited from the Masivukeni intervention - were 12x as likely to have suppressed VL at ~ 2 years post ART-initiation (compared to SOC).

- Interestingly, Masivukeni was initially developed for “defaulters”

- We think that the depth of learning (with visual imagery) about HIV treatment & importance of adherence, along with enhancing treatment support and problem solving skills, contributed to this positive outcome.

- It may be that enhanced interventions, like Masivukeni, are needed and most beneficial for patients who struggle early on with adherence.
Masivukeni appears to have advantages over SOC in the following ways:

- Contributes to increased likelihood for women to initiate ART
- Enhances “buddy support” contributing to better adherence and patient health outcomes
- Improves longer-term viral suppression among patients who are unsuccessful in achieving viral suppression in the early phase after ART initiation
- Enhances lay counselor comfort with, and capacity for, delivering adherence counseling to patients and their treatment support partners
Provincial and City Health Department policy-makers -- and ATICC / People Development Centre personnel -- are interested in scaling up the use of Masivukeni for all counselors in the setting for the following reasons:

- It has “some” clinical benefits for patients
- Counselors like utilizing the multi-media intervention
- The intervention “tool” has the ability to scale-up a standardized adherence counseling platform, with the ability to adapt it with evolving treatment information
- The “tool” has the ability to track counseling delivery (with back-end data) for monitoring of service delivery, quality insurance, and providing ongoing support for counselors
Acknowledgements

HIV Center, NYSPI and Columbia University
Robert H. Remien, Ph.D.
Reuben N. Robbins, Ph.D.
Claude Ann Mellins, Ph.D.
Javier López-Rios, B.A.
Cheng-Shiun Leu, Ph.D.
Bruce Levin, Ph.D.
Patricia Warne, Ph.D.

University of Cape Town
John Joska, M.B.Ch.B.
Hetta Gouse, Ph.D.
Michelle Henry
Yoliswa Mtigeni

National Institute of Mental Health
“Masivukeni: A Multimedia ART Adherence Intervention for Resource-Limited Settings
(R01-MH95576; PI: Robert H. Remien, Ph.D.)

NIMH Program Officer: Michael Stirratt, Ph.D.

HIV Center for Clinical and Behavioral Studies
(P30-MH43520; Center Director and PI: Robert H. Remien, Ph.D.)
This research was supported by NIMH grants (R34 MH82654; R01-MH95576-05; PI: Remien) and a NIMH center grant (P30-MH43520; PI: Remien).